Chai Discovery raises $30 million in financing to revolutionize drug discovery with AI
Chai Discovery is a biotechnology startup focused on artificial intelligence that has raised nearly $30 million in funding from Thrive Capital and OpenAI in just six months after its establishment. The investment values the company to $150 million
。Chai’s goal is to transform the drug discovery process by developing AI models that can predict biochemical structures and interactions, thereby improving the drug development process.
The company’s first open source model, Chai-1, claims to be 10% to 20% better on key drug discovery tasks than existing tools such as AlphaFold. Co-founder Joshua Meier emphasized that their goal is to engineer biology, not just study it. Chai has fewer than ten employees, and its talents come from major technology companies such as Google and Meta. In a highly competitive market, biopharmaceutical startups attracted nearly $30 billion in venture capital in 2023 alone.
As the AI-driven drug discovery market continues to expand–which industry experts predict could exceed $100 billion–Chai’s innovative approach makes it an important player in competition with established giants such as Google and other start-ups.
For more content, you can click on the link below the video
Thank you for watching this video. If you like it, please subscribe and like it. thank
Bloomberg Original:https://www.bloomberg.com/news/articles/2024-09-09/openai-thrive-capital-back-six-month-old-ai-drug-discovery-startup
Oil tubing: